Praedicare utilizes several quantitative platforms [wet lab studies, mathematical modeling, in silico simulations, and proprietary algorithms] for drug development and testing in the areas of treatment for infection, oncology, immunotherapeutics, and toxicology, among others. We work with clients to take a drug from lead optimization, through IND filing, to phase I clinical trial design. Our platforms allow for rapid development of combination regimens and the ratios of does in the combinations as well as comparisons to the standard of care. Thus, Praedicare de-risks the drug development process for clients in terms of time, money and effort. Praedicare achieves this by offering services that allowEarly choices and decision-making for which drugs/compounds are likely to be successful candidates for further development,Pre-clinical drug development with output that has high quantitative forecasting accuracy of clinical events,Reducing the number of doses to be tested to a single optimal dose for early phase "first in man" and dose-ranging studies,Design of combination regimens in months rather than the decades-long iterative process of replacing a single drug to existing combinations, andTakes into account the pediatric use of drugs early in the drug-development process.